TrialEuropean urology2022

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.

Laurence Albiges et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.